r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

SA

Srinivas Akkaraju

Insider · Director · ALMS

Srinivas Akkaraju files insider transactions with the SEC as a director of Alumis. We hold 6 disclosed purchases and sales filed since 10 April 2006, 3 of them in the last 90 days.

  • Files for 20 companiesALMS, VTVT, SRRK, KLRS and 16 more
  • Disclosed buys and sells6 in all, 3 in the last 90 days
  • Last disclosure9 September 2026

Positions held

20 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 1 July 2024 — 8 September 2026Director · Alumis 34 Form 4 lines · source: SEC Form 4
  • Filed 27 February 2024 — 26 June 2026Director · vTv Therapeutics 14 Form 4 lines · source: SEC Form 4
  • Filed 16 September 2022 — 4 June 2026Director · Scholar Rock Holding 23 Form 4 lines · source: SEC Form 4
  • Filed 18 March 2025 — 3 June 2026Director · Kalaris Therapeutics 9 Form 4 lines · source: SEC Form 4
  • Filed 14 February 2023 — 19 February 2026Director and 10% owner · Mineralys Therapeutics 12 Form 4 lines · source: SEC Form 4
  • Filed 26 November 2024 — 26 November 202410% owner · Neurogene 4 Form 4 lines · source: SEC Form 4
  • Filed 8 June 2017 — 16 September 2024Director · Syros Pharmaceuticals 38 Form 4 lines · source: SEC Form 4
  • Filed 14 November 2023 — 14 November 202310% owner · CARGO Therapeutics 5 Form 4 lines · source: SEC Form 4
  • Filed 16 October 2012 — 8 November 2023Director · Intercept Pharmaceuticals 87 Form 4 lines · source: SEC Form 4
  • Filed 5 October 2020 — 11 August 2023Director · Chinook Therapeutics 15 Form 4 lines · source: SEC Form 4
  • Filed 29 June 2021 — 12 April 202210% owner · Graphite Bio 18 Form 4 lines · source: SEC Form 4
  • Filed 9 December 2020 — 23 September 2021Director and 10% owner · Jiya Acquisition 5 Form 4 lines · source: SEC Form 4
  • Filed 6 April 2006 — 15 May 2020Director · Seattle Genetics Inc /wa 194 Form 4 lines · source: SEC Form 4
  • Filed 12 October 2018 — 2 December 2019Director · Aravive 5 Form 4 lines · source: SEC Form 4
  • Filed 13 September 2018 — 18 September 2018Director · Principia Biopharma 4 Form 4 lines · source: SEC Form 4
  • Filed 20 March 2014 — 13 June 2018Director · Versartis 17 Form 4 lines · source: SEC Form 4
  • Filed 12 May 2015 — 9 May 2017Director · aTYR PHARMA 7 Form 4 lines · source: SEC Form 4
  • Filed 22 August 2014 — 17 December 2015Director · ZS Pharma 6 Form 4 lines · source: SEC Form 4
  • Filed 20 December 2011 — 27 June 2012Other role · Synageva Biopharma 5 Form 4 lines · source: SEC Form 4
  • Filed 11 May 2009 — 5 January 2011Director · Pharmos 5 Form 4 lines · source: SEC Form 4

Every transaction

the 400 most recent transactions from SEC Form 4 — one row each, sort any column, open a row for the filing; this is the most recent page of them
400 of 400 shown — the most recent we hold
4 Jun 20268 Jun 2026SEC Form 44 dwas grantednot a tradeScholar Rock Holding6,839 sharesup +20.5%up +24.7%
4 Jun 20268 Jun 2026SEC Form 44 dwas grantednot a tradeScholar Rock Holdingderivative4,310 sharesup +20.5%up +24.7%
3 Jun 20264 Jun 2026SEC Form 41 dwas grantednot a tradeKalaris Therapeuticsderivative9,000 sharesdown −26.5%down −25.5%
22 May 202523 May 2025SEC Form 41 dwas grantednot a tradeScholar Rock Holdingderivative9,206 sharesup +79.3%up +82.1%
22 May 202523 May 2025SEC Form 41 dwas grantednot a tradeScholar Rock Holding7,632 sharesup +79.3%up +82.1%
10 Apr 202511 Apr 2025SEC Form 41 dwas grantednot a tradeKalaris Therapeuticsderivative18,000 sharesdown −52.5%down −52.0%
18 Mar 202518 Mar 2025SEC Form 40 dwas grantednot a tradeKalaris Therapeutics11,444,503 sharesdown −64.6%down −64.6%
16 Sep 202418 Sep 2024SEC Form 42 dexercised options overnot a tradeSYRSSyros Pharmaceuticalsderivative2,667 shares——
16 Sep 202418 Sep 2024SEC Form 42 dexercised options overnot a tradeSYRSSyros Pharmaceuticals2,667 shares——
5 Jun 20247 Jun 2024SEC Form 42 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative6,000 shares——
5 Jun 20247 Jun 2024SEC Form 42 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative4,000 shares——
1 Jun 20244 Jun 2024SEC Form 43 dexercised options overnot a tradeSYRSSyros Pharmaceuticalsderivative4,000 shares——
1 Jun 20244 Jun 2024SEC Form 43 dexercised options overnot a tradeSYRSSyros Pharmaceuticals4,000 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative12,089 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative12,790 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative12,547 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative275 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative1,750 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative1,598 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative2,036 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative2,748 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative2,174 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticalsderivative2,966 shares——
8 Nov 202313 Nov 2023SEC Form 45 ddisposed of in a tender offernot a tradeICPTIntercept Pharmaceuticals37,887 shares——
8 Nov 202313 Nov 2023SEC Form 45 ddisposed of in a tender offernot a tradeICPTIntercept Pharmaceuticals640,688 shares——
8 Nov 202313 Nov 2023SEC Form 45 dreturned to the issuernot a tradeICPTIntercept Pharmaceuticals8,111 shares——
24 May 202325 May 2023SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative12,547 shares——
24 May 202325 May 2023SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticals8,111 shares——
16 Sep 202220 Sep 2022SEC Form 44 dwas grantednot a tradeScholar Rock Holdingderivative56,000 sharesup +513.0%up +517.2%
25 May 202227 May 2022SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative12,790 shares——
25 May 202227 May 2022SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals7,737 shares——
11 Apr 202213 Apr 2022SEC Form 42 dbought on the open marketGraphite Bio74,464 sharesdown −82.8%down −83.1%
24 Jan 202225 Jan 2022SEC Form 41 dbought on the open marketGraphite Bio23,000 sharesdown −92.3%down −92.1%
21 Jan 202225 Jan 2022SEC Form 44 dbought on the open marketGraphite Bio100,000 sharesdown −92.2%down −92.1%
20 Jan 202221 Jan 2022SEC Form 41 dbought on the open marketGraphite Bio43,105 sharesdown −92.2%down −92.2%
19 Jan 202221 Jan 2022SEC Form 42 dbought on the open marketGraphite Bio54,565 sharesdown −92.2%down −92.2%
22 Nov 202124 Nov 2021SEC Form 42 dbought on the open marketGraphite Bio201,685 sharesdown −92.3%down −93.0%
15 Nov 202117 Nov 2021SEC Form 42 dbought on the open marketKDNYChinook Therapeutics1,215,000 shares——
8 Oct 20218 Oct 2021SEC Form 40 dbought on the open marketGraphite Bio75,000 sharesdown −94.7%down −94.7%
7 Oct 20218 Oct 2021SEC Form 41 dbought on the open marketGraphite Bio9,021 sharesdown −95.3%down −94.7%
6 Oct 20218 Oct 2021SEC Form 42 dbought on the open marketGraphite Bio61,475 sharesdown −95.0%down −94.7%
23 Sep 202127 Sep 2021SEC Form 44 dacquired or disposed of, othernot a tradeJYACJiya Acquisitionderivative30,000 shares——
23 Sep 202127 Sep 2021SEC Form 44 dacquired or disposed of, othernot a tradeJYACJiya Acquisitionderivative30,000 shares——
26 Aug 202130 Aug 2021SEC Form 44 dacquired or disposed of, othernot a tradeJYACJiya Acquisitionderivative5,000 shares——
18 Aug 202120 Aug 2021SEC Form 42 dbought on the open marketKDNYChinook Therapeutics208,500 shares——
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bioderivative15,000,000 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bioderivative1,802,372 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bioderivative55,336 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bio6,167,763 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bio741,107 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeGraphite Bio22,753 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dbought on the open marketGraphite Bio485,000 sharesdown −97.5%down −97.5%
29 Jun 20211 Jul 2021SEC Form 42 dbought on the open marketGraphite Bio15,000 sharesdown −97.5%down −97.5%
8 Jun 202110 Jun 2021SEC Form 42 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative17,500 shares——
4 Jun 20218 Jun 2021SEC Form 44 dwas grantednot a tradeKDNYChinook Therapeuticsderivative5,948 shares——
27 May 20211 Jun 2021SEC Form 45 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative12,089 shares——
27 May 20211 Jun 2021SEC Form 45 dwas grantednot a tradeICPTIntercept Pharmaceuticals7,029 shares——
13 Apr 202115 Apr 2021SEC Form 42 dacquired or disposed of, othernot a tradeJYACJiya Acquisitionderivative5,000 shares——
12 Mar 202112 Mar 2021SEC Form 40 dbought on the open marketICPTIntercept Pharmaceuticals147,000 shares——
10 Mar 202112 Mar 2021SEC Form 42 dbought on the open marketICPTIntercept Pharmaceuticals73,441 shares——
10 Mar 202112 Mar 2021SEC Form 42 dbought on the open marketICPTIntercept Pharmaceuticals16,559 shares——
9 Dec 202011 Dec 2020SEC Form 42 dwas grantednot a tradeJYACJiya Acquisition7,041 shares——
8 Dec 202011 Dec 2020SEC Form 43 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative156,250 shares——
8 Dec 202011 Dec 2020SEC Form 43 dwas grantednot a tradeSYRSSyros Pharmaceuticals625,000 shares——
6 Oct 20207 Oct 2020SEC Form 41 dwas grantednot a tradeKDNYAduro Biotechderivative23,522 shares——
5 Oct 20207 Oct 2020SEC Form 42 dwas grantednot a tradeKDNYAduro Biotech3,168,388 shares——
18 Aug 202019 Aug 2020SEC Form 41 dsold on the open marketSYRSSyros Pharmaceuticals158,583 shares——
17 Aug 202019 Aug 2020SEC Form 42 dsold on the open marketSYRSSyros Pharmaceuticals744 shares——
1 Jul 20206 Jul 2020SEC Form 45 dsold on the open marketSYRSSyros Pharmaceuticals4,627 shares——
25 Jun 202025 Jun 2020SEC Form 40 dsold on the open marketSYRSSyros Pharmaceuticals54,972 shares——
24 Jun 202025 Jun 2020SEC Form 41 dsold on the open marketSYRSSyros Pharmaceuticals48,775 shares——
23 Jun 202025 Jun 2020SEC Form 42 dsold on the open marketSYRSSyros Pharmaceuticals50,953 shares——
11 Jun 202011 Jun 2020SEC Form 40 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative17,500 shares——
28 May 20201 Jun 2020SEC Form 44 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative2,966 shares——
28 May 20201 Jun 2020SEC Form 44 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,595 shares——
15 May 202019 May 2020SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative3,171 shares——
15 May 202019 May 2020SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa1,335 shares——
5 May 20207 May 2020SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative8,500 shares——
5 May 20207 May 2020SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa8,500 shares——
5 May 20207 May 2020SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa8,500 shares——
2 Dec 20192 Dec 2019SEC Form 40 dbought on the open marketARAVAravive133,333 shares——
21 Nov 201922 Nov 2019SEC Form 41 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative12,558 shares——
21 Nov 201922 Nov 2019SEC Form 41 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative4,942 shares——
21 Nov 201922 Nov 2019SEC Form 41 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa12,558 shares——
21 Nov 201922 Nov 2019SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa12,558 shares——
21 Nov 201922 Nov 2019SEC Form 41 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa4,942 shares——
21 Nov 201922 Nov 2019SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa4,942 shares——
12 Sep 201913 Sep 2019SEC Form 41 dwas grantednot a tradeARAVAravivederivative7,500 shares——
28 Aug 201930 Aug 2019SEC Form 42 dbought on the open marketICPTIntercept Pharmaceuticals5,207 shares——
22 Aug 201923 Aug 2019SEC Form 41 dbought on the open marketICPTIntercept Pharmaceuticals1,180 shares——
22 Aug 201922 Aug 2019SEC Form 40 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,180 shares——
21 Aug 201923 Aug 2019SEC Form 42 dbought on the open marketICPTIntercept Pharmaceuticals29,000 shares——
21 Aug 201922 Aug 2019SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticals29,000 shares——
20 Aug 201923 Aug 2019SEC Form 43 dbought on the open marketICPTIntercept Pharmaceuticals37,604 shares——
20 Aug 201922 Aug 2019SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals37,604 shares——
20 Jun 201921 Jun 2019SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative2,174 shares——
20 Jun 201921 Jun 2019SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,570 shares——
11 Jun 201912 Jun 2019SEC Form 41 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative11,000 shares——
20 May 201922 May 2019SEC Form 42 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative7,038 shares——
20 May 201922 May 2019SEC Form 42 dwas grantednot a tradeSGENSeattle Genetics Inc /wa2,963 shares——
14 May 201914 May 2019SEC Form 40 dwas grantednot a tradeICPTIntercept Pharmaceuticals119,760 shares——
25 Apr 201929 Apr 2019SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative2,499 shares——
25 Apr 201929 Apr 2019SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative1,001 shares——
25 Apr 201929 Apr 2019SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticals2,499 shares——
25 Apr 201929 Apr 2019SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticals1,001 shares——
9 Apr 201911 Apr 2019SEC Form 42 dbought on the open marketnot a tradeSYRSSyros Pharmaceuticalsderivative133,333 shares——
9 Apr 201911 Apr 2019SEC Form 42 dbought on the open marketSYRSSyros Pharmaceuticals533,332 shares——
19 Feb 201921 Feb 2019SEC Form 42 dsold on the open marketICPTIntercept Pharmaceuticals23,438 shares——
30 Oct 20181 Nov 2018SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa5,000 shares——
30 Oct 20181 Nov 2018SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative5,000 shares——
12 Oct 201816 Oct 2018SEC Form 44 dwas grantednot a tradeARAVAravive27,456 shares——
18 Sep 201820 Sep 2018SEC Form 42 dconvertednot a tradePRNBPrincipia Biopharmaderivative208,480 shares——
18 Sep 201820 Sep 2018SEC Form 42 dconvertednot a tradePRNBPrincipia Biopharma208,480 shares——
18 Sep 201820 Sep 2018SEC Form 42 dbought on the open marketPRNBPrincipia Biopharma175,000 shares——
13 Sep 201810 Jan 2019SEC Form 4119 dwas grantednot a tradePRNBPrincipia Biopharmaderivative20,475 shares——
20 Jun 201822 Jun 2018SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative2,748 shares——
20 Jun 201822 Jun 2018SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,787 shares——
14 Jun 201815 Jun 2018SEC Form 41 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative11,000 shares——
13 Jun 201815 Jun 2018SEC Form 42 dbought on the open marketVSARVersartis53,018 shares——
8 Jun 20188 Jun 2018SEC Form 40 dbought on the open marketVSARVersartis231,580 shares——
7 Jun 20188 Jun 2018SEC Form 41 dbought on the open marketVSARVersartis163,224 shares——
6 Jun 20188 Jun 2018SEC Form 42 dbought on the open marketVSARVersartis660,681 shares——
18 May 201822 May 2018SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative9,260 shares——
18 May 201822 May 2018SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,700 shares——
5 Apr 20189 Apr 2018SEC Form 44 dwas grantednot a tradeICPTIntercept Pharmaceuticals234,375 shares——
31 Jan 20182 Feb 2018SEC Form 42 dbought on the open marketSYRSSyros Pharmaceuticals209,424 shares——
20 Dec 201722 Dec 2017SEC Form 42 dwas grantednot a tradeVSARVersartis11,200 shares——
14 Dec 201714 Dec 2017SEC Form 40 dbought on the open marketSYRSSyros Pharmaceuticals26,600 shares——
13 Dec 201714 Dec 2017SEC Form 41 dbought on the open marketSYRSSyros Pharmaceuticals68,400 shares——
12 Dec 201714 Dec 2017SEC Form 42 dbought on the open marketSYRSSyros Pharmaceuticals14,774 shares——
5 Dec 20175 Dec 2017SEC Form 40 dbought on the open marketVSARVersartis42,895 shares——
4 Dec 20175 Dec 2017SEC Form 41 dbought on the open marketVSARVersartis513,872 shares——
1 Dec 20175 Dec 2017SEC Form 44 dbought on the open marketVSARVersartis419,700 shares——
27 Jun 201729 Jun 2017SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,423 shares——
27 Jun 201729 Jun 2017SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative2,036 shares——
8 Jun 201722 Sep 2017SEC Form 4106 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative22,000 shares——
8 Jun 201712 Jun 2017SEC Form 44 dwas grantednot a tradeSYRSSyros Pharmaceuticalsderivative22,000 shares——
25 May 20176 Jun 2017SEC Form 412 dwas grantednot a tradeVSARVersartis3,480 shares——
25 May 20176 Jun 2017SEC Form 412 dwas grantednot a tradeVSARVersartisderivative6,850 shares——
19 May 201723 May 2017SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,700 shares——
19 May 201723 May 2017SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative9,260 shares——
9 May 201711 May 2017SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative20,000 sharesdown −99.0%down −99.0%
24 Mar 201728 Mar 2017SEC Form 44 dbought on the open marketVSARVersartis571,429 shares——
3 Oct 20164 Oct 2016SEC Form 41 dbought on the open marketVSARVersartis571,429 shares——
19 Jul 201621 Jul 2016SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,204 shares——
19 Jul 201621 Jul 2016SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative1,598 shares——
14 Jun 201620 Jun 2016SEC Form 46 dwas grantednot a tradeVSARVersartis6,900 shares——
14 Jun 201620 Jun 2016SEC Form 46 dwas grantednot a tradeVSARVersartisderivative28,720 shares——
24 May 201626 May 2016SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative18,000 sharesdown −99.0%down −99.0%
20 May 201624 May 2016SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,700 shares——
20 May 201624 May 2016SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative9,260 shares——
13 May 201617 May 2016SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticals1,500 shares——
13 May 201617 May 2016SEC Form 44 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative1,500 shares——
27 Jan 201629 Jan 2016SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative19,428 sharesdown −99.5%down −99.4%
17 Dec 201521 Dec 2015SEC Form 44 dreturned to the issuernot a tradeZS Pharma1,000 shares——
17 Dec 201521 Dec 2015SEC Form 44 dreturned to the issuernot a tradeZS Pharmaderivative12,000 shares——
17 Dec 201521 Dec 2015SEC Form 44 dreturned to the issuernot a tradeZS Pharmaderivative4,000 shares——
24 Nov 201527 Nov 2015SEC Form 43 dwas grantednot a tradeICPTIntercept Pharmaceuticals650 shares——
24 Nov 201527 Nov 2015SEC Form 43 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative1,750 shares——
28 Oct 201530 Oct 2015SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticals1,250 shares——
28 Oct 201530 Oct 2015SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative1,250 shares——
8 Jul 201510 Jul 2015SEC Form 42 dwas grantednot a tradeaTYR PHARMAderivative6,286 sharesdown −99.8%down −99.8%
29 Jun 20151 Jul 2015SEC Form 42 dwas grantednot a tradeVSARVersartis4,575 shares——
29 Jun 20151 Jul 2015SEC Form 42 dwas grantednot a tradeVSARVersartisderivative13,100 shares——
18 Jun 201529 Jun 2015SEC Form 411 dwas grantednot a tradeZS Pharmaderivative4,000 shares——
18 Jun 201529 Jun 2015SEC Form 411 dwas grantednot a tradeZS Pharmaderivative1,000 shares——
19 May 201522 May 2015SEC Form 43 dexercised options overnot a tradeICPTIntercept Pharmaceuticals1,000 shares——
19 May 201522 May 2015SEC Form 43 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative1,000 shares——
15 May 201519 May 2015SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,700 shares——
15 May 201519 May 2015SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative9,260 shares——
12 May 201514 May 2015SEC Form 42 dconvertednot a tradeaTYR PHARMA1,546,126 sharesdown −99.8%down −99.8%
12 May 201514 May 2015SEC Form 42 dbought on the open marketaTYR PHARMA320,000 sharesdown −99.8%down −99.8%
12 May 201514 May 2015SEC Form 42 dconvertednot a tradeaTYR PHARMAderivative14,968,722 sharesdown −99.8%down −99.8%
12 Nov 201413 Nov 2014SEC Form 41 dbought on the open marketICPTIntercept Pharmaceuticals500 shares——
12 Nov 201413 Nov 2014SEC Form 41 dbought on the open marketICPTIntercept Pharmaceuticals1,000 shares——
12 Nov 201413 Nov 2014SEC Form 41 dbought on the open marketICPTIntercept Pharmaceuticals500 shares——
11 Nov 201413 Nov 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticals2,500 shares——
11 Nov 201413 Nov 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative2,500 shares——
16 Oct 20145 Nov 2014SEC Form 420 dexercised options overnot a tradeICPTIntercept Pharmaceuticals324 shares——
16 Oct 20145 Nov 2014SEC Form 420 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative324 shares——
22 Aug 201426 Aug 2014SEC Form 44 dwas grantednot a tradeZS Pharmaderivative12,000 shares——
17 Jul 201418 Jul 2014SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticals226 shares——
17 Jul 201418 Jul 2014SEC Form 41 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative275 shares——
16 Jul 201418 Jul 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticals325 shares——
16 Jul 201418 Jul 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative325 shares——
16 May 201420 May 2014SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,500 shares——
16 May 201420 May 2014SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative8,750 shares——
16 Apr 201418 Apr 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticals324 shares——
16 Apr 201418 Apr 2014SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative324 shares——
20 Mar 201424 Mar 2014SEC Form 44 dwas grantednot a tradeVSARVersartisderivative35,000 shares——
16 Jan 201417 Jan 2014SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticals325 shares——
16 Jan 201417 Jan 2014SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticals2,500 shares——
16 Jan 201417 Jan 2014SEC Form 41 dsold on the open marketICPTIntercept Pharmaceuticals3,250 shares——
16 Jan 201417 Jan 2014SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative325 shares——
16 Jan 201417 Jan 2014SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative2,500 shares——
18 Dec 201319 Dec 2013SEC Form 41 dsold on the open marketICPTIntercept Pharmaceuticals260 shares——
16 Oct 201321 Oct 2013SEC Form 45 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative324 shares——
16 Oct 201321 Oct 2013SEC Form 45 dexercised options overnot a tradeICPTIntercept Pharmaceuticals324 shares——
16 Jul 201316 Jul 2013SEC Form 40 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative325 shares——
16 Jul 201316 Jul 2013SEC Form 40 dexercised options overnot a tradeICPTIntercept Pharmaceuticals325 shares——
14 Jun 201317 Jun 2013SEC Form 43 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative5,000 shares——
14 Jun 201317 Jun 2013SEC Form 43 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa5,000 shares——
14 Jun 201317 Jun 2013SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa5,000 shares——
17 May 201321 May 2013SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative8,750 shares——
17 May 201321 May 2013SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /wa3,500 shares——
10 May 201314 May 2013SEC Form 44 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative17,500 shares——
10 May 201314 May 2013SEC Form 44 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa17,500 shares——
10 May 201314 May 2013SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa17,500 shares——
7 May 20139 May 2013SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative1,980 shares——
7 May 20139 May 2013SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticals1,330 shares——
24 Apr 201326 Apr 2013SEC Form 42 dacquired or disposed of, othernot a tradeICPTIntercept Pharmaceuticals700,000 shares——
16 Apr 201317 Apr 2013SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative324 shares——
16 Apr 201317 Apr 2013SEC Form 41 dexercised options overnot a tradeICPTIntercept Pharmaceuticals324 shares——
9 Apr 201311 Apr 2013SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticalsderivative325 shares——
9 Apr 201311 Apr 2013SEC Form 42 dexercised options overnot a tradeICPTIntercept Pharmaceuticals325 shares——
18 Nov 201220 Nov 2012SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative2,596 shares——
18 Nov 201220 Nov 2012SEC Form 42 dwas grantednot a tradeICPTIntercept Pharmaceuticalsderivative11,249 shares——
16 Oct 201216 Oct 2012SEC Form 40 dbought on the open marketICPTIntercept Pharmaceuticals700,000 shares——
27 Jun 201228 Jun 2012SEC Form 41 dsold on the open marketSynageva Biopharma313,451 shares——
26 Jun 201228 Jun 2012SEC Form 42 dsold on the open marketSynageva Biopharma28,827 shares——
18 May 201223 May 2012SEC Form 45 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative17,500 shares——
19 Mar 201221 Mar 2012SEC Form 42 dsold on the open marketSynageva Biopharma342,278 shares——
20 Dec 201111 Jan 2012SEC Form 422 dwas grantednot a tradeSynageva Biopharmaderivative15,000 shares——
20 Dec 201121 Dec 2011SEC Form 41 dwas grantednot a tradeSynageva Biopharmaderivative15,000 shares——
20 May 201124 May 2011SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative17,500 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dacquired or disposed of, othernot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dacquired or disposed of, othernot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dacquired or disposed of, othernot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dacquired or disposed of, othernot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dexercised options overnot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 Jun 201023 Jun 2010SEC Form 42 dacquired or disposed of, othernot a tradeSGENSeattle Genetics Inc /wa10,000 shares——
21 May 201025 May 2010SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative17,500 shares——
18 Aug 200920 Aug 2009SEC Form 42 dbought on the open marketSGENSeattle Genetics Inc /wa4,905 shares——
25 Jun 200929 Jun 2009SEC Form 44 dbought on the open marketSGENSeattle Genetics Inc /wa2,200 shares——
25 Jun 200929 Jun 2009SEC Form 44 dbought on the open marketSGENSeattle Genetics Inc /wa2,700 shares——
25 Jun 200929 Jun 2009SEC Form 44 dbought on the open marketSGENSeattle Genetics Inc /wa600 shares——
15 May 200919 May 2009SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa10,751 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa2,322 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa317 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa1,178 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa131 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa873 shares——
22 Sep 200823 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa3,029 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa50,685 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa10,947 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa1,492 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa5,556 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa619 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa4,114 shares——
19 Sep 200824 Sep 2008SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa14,283 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa10,947 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa1,492 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa5,556 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa619 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa4,114 shares——
19 Sep 200822 Sep 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa14,283 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa28,539 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa6,164 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa840 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa3,128 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa349 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa2,316 shares——
18 Sep 200824 Sep 2008SEC Form 46 dsold on the open marketSGENSeattle Genetics Inc /wa8,042 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa6,164 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa840 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa3,128 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa349 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa2,316 shares——
18 Sep 200819 Sep 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa8,042 shares——
6 Aug 20088 Aug 2008SEC Form 42 dreturned to the issuernot a tradeBarrier Therapeuticsderivative10,000 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics2,005,715 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics332,807 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics168,617 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics46,312 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics18,801 shares——
5 Aug 20088 Aug 2008SEC Form 43 ddisposed of in a tender offernot a tradeBarrier Therapeutics84,588 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa17,290 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa2,357 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa8,776 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa978 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa6,498 shares——
29 Jul 200830 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa59,789 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa2,650 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa361 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa1,345 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa150 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa996 shares——
28 Jul 200829 Jul 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa15,730 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa18,491 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa2,521 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa9,386 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa1,046 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa6,949 shares——
25 Jul 200828 Jul 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa109,743 shares——
1 Jul 20083 Jul 2008SEC Form 42 dwas grantednot a tradePharmosderivative20,000 shares——
16 May 200819 May 2008SEC Form 43 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa5,250 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa716 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa2,664 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa297 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa1,973 shares——
16 May 200819 May 2008SEC Form 43 dsold on the open marketSGENSeattle Genetics Inc /wa31,159 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa12,328 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa1,681 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa6,257 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa697 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa4,633 shares——
15 May 200819 May 2008SEC Form 44 dsold on the open marketSGENSeattle Genetics Inc /wa73,162 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa15,150 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa2,065 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa7,689 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa857 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa5,693 shares——
14 May 200815 May 2008SEC Form 41 dsold on the open marketSGENSeattle Genetics Inc /wa89,911 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa6,353 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa866 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa3,224 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa360 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa2,388 shares——
13 May 200815 May 2008SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa37,705 shares——
23 Jan 200825 Jan 2008SEC Form 42 dwas grantednot a tradePharmosderivative20,000 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa2,616 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa357 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa1,328 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa148 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa983 shares——
10 Dec 200712 Dec 2007SEC Form 42 dsold on the open marketSGENSeattle Genetics Inc /wa15,528 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative226,398 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative55,985 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative7,632 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative28,416 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative3,166 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative21,039 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa2,263,980 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa559,850 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa76,320 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa284,160 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa31,660 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa210,390 shares——
9 Jul 200712 Dec 2007SEC Form 4156 dconvertednot a tradeSGENSeattle Genetics Inc /wa1,058,640 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative226,398 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative55,985 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative7,632 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative28,416 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative3,166 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative21,039 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa2,263,980 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa559,850 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa284,160 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa76,320 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa31,660 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa210,390 shares——
9 Jul 200713 Jul 2007SEC Form 44 dconvertednot a tradeSGENSeattle Genetics Inc /wa1,058,640 shares——
6 Jun 20078 Jun 2007SEC Form 42 dwas grantednot a tradeBarrier Therapeuticsderivative10,000 shares——
25 May 200730 May 2007SEC Form 45 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative149,278 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative25,152 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative3,429 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative12,766 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative1,423 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /waderivative9,452 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa1,492,780 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa251,520 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa34,429 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa127,660 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa14,230 shares——
9 Feb 200714 Feb 2007SEC Form 45 dconvertednot a tradeSGENSeattle Genetics Inc /wa94,520 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa1,492,780 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa251,520 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa34,290 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa127,660 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa14,230 shares——
9 Feb 200714 Feb 2007SEC Form 45 dsold on the open marketSGENSeattle Genetics Inc /wa94,520 shares——
19 May 200623 May 2006SEC Form 44 dwas grantednot a tradeSGENSeattle Genetics Inc /waderivative10,000 shares——
6 Apr 200610 Apr 2006SEC Form 44 dsold on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative132,331 shares——
6 Apr 200610 Apr 2006SEC Form 44 dbought on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative132,331 shares——
6 Apr 200610 Apr 2006SEC Form 44 dsold on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
6 Apr 200610 Apr 2006SEC Form 44 dbought on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
6 Apr 200610 Apr 2006SEC Form 44 dsold on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative132,331 shares——
6 Apr 200610 Apr 2006SEC Form 44 dbought on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative132,331 shares——
6 Apr 200610 Apr 2006SEC Form 44 dsold on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
6 Apr 200610 Apr 2006SEC Form 44 dbought on the open marketnot a tradeSGENSeattle Genetics Inc /waderivative105,864 shares——
17 Jan 200619 Jan 2007SEC Form 4367 dwas grantednot a tradePharmosderivative20,000 shares——
15 Feb 20058 Jun 2007SEC Form 4843 dsold on the open marketBarrier Therapeutics380,497 shares——
15 Feb 20058 Jun 2007SEC Form 4843 dsold on the open marketBarrier Therapeutics65,168 shares——
15 Feb 20058 Jun 2007SEC Form 4843 dsold on the open marketBarrier Therapeutics33,018 shares——
15 Feb 20058 Jun 2007SEC Form 4843 dsold on the open marketBarrier Therapeutics9,068 shares——
15 Feb 20058 Jun 2007SEC Form 4843 dsold on the open marketBarrier Therapeutics3,682 shares——

Both percentages are the stock’s move, not Srinivas Akkaraju’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 32 of the 400 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.